BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Frymoyer A, Hersh AL, El-Komy MH, Gaskari S, Su F, Drover DR, Van Meurs K. Association between vancomycin trough concentration and area under the concentration-time curve in neonates. Antimicrob Agents Chemother 2014;58:6454-61. [PMID: 25136027 DOI: 10.1128/AAC.03620-14] [Cited by in Crossref: 66] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Wang Y, Gao P, Zhang H, Chen Y, Niu C, Liu M, Li S, Xu Q, Ye Q. How Much Vancomycin Dose Is Enough For The MRSA Infection in Pediatric Patients With Various Degrees of Renal Function? Iran J Pharm Res 2019;18:995-1009. [PMID: 31531080 DOI: 10.22037/ijpr.2019.1100654] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Chen Y, Wu D, Dong M, Zhu Y, Lu J, Li X, Chen C, Li Z. Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants. Eur J Clin Pharmacol 2018;74:921-30. [PMID: 29602981 DOI: 10.1007/s00228-018-2454-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
3 Janssen EJ, Välitalo PA, Allegaert K, de Cock RF, Simons SH, Sherwin CM, Mouton JW, van den Anker JN, Knibbe CA. Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling. Antimicrob Agents Chemother 2016;60:1013-21. [PMID: 26643337 DOI: 10.1128/AAC.01968-15] [Cited by in Crossref: 43] [Cited by in F6Publishing: 19] [Article Influence: 6.1] [Reference Citation Analysis]
4 Tseng SH, Lim CP, Chen Q, Tang CC, Kong ST, Ho PC. Evaluating the Relationship between Vancomycin Trough Concentration and 24-Hour Area under the Concentration-Time Curve in Neonates. Antimicrob Agents Chemother 2018;62:e01647-17. [PMID: 29358290 DOI: 10.1128/AAC.01647-17] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
5 Cristea S, Allegaert K, Falcao AC, Falcao F, Silva R, Smits A, Knibbe CAJ, Krekels EHJ. Larger Dose Reductions of Vancomycin Required in Neonates with Patent Ductus Arteriosus Receiving Indomethacin versus Ibuprofen. Antimicrob Agents Chemother 2019;63:e00853-19. [PMID: 31182538 DOI: 10.1128/AAC.00853-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
6 Monteiro JF, Hahn SR, Gonçalves J, Fresco P. Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations. Pharmacol Res Perspect 2018;6:e00420. [PMID: 30156005 DOI: 10.1002/prp2.420] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
7 Stone SB, Benner K, Utley A, MacLennan P, Coghill CH 3rd. Achieving Vancomycin Troughs Within Goal Range in Low Birth Weight Neonates. J Pediatr Pharmacol Ther 2021;26:56-61. [PMID: 33424501 DOI: 10.5863/1551-6776-26.1.56] [Reference Citation Analysis]
8 Huang X, Yu Z, Bu S, Lin Z, Hao X, He W, Yu P, Wang Z, Gao F, Zhang J, Chen J. An Ensemble Model for Prediction of Vancomycin Trough Concentrations in Pediatric Patients. Drug Des Devel Ther 2021;15:1549-59. [PMID: 33883878 DOI: 10.2147/DDDT.S299037] [Reference Citation Analysis]
9 Sasano H, Aoki K, Arakawa R, Hanada K. Population Pharmacokinetic Analysis and Dose Regimen Optimization in Japanese Infants with an Extremely Low Birth Weight. Antimicrob Agents Chemother 2021;65:e02523-20. [PMID: 33318009 DOI: 10.1128/AAC.02523-20] [Reference Citation Analysis]
10 Mukhopadhyay S, Wade KC, Puopolo KM. Drugs for the Prevention and Treatment of Sepsis in the Newborn. Clin Perinatol 2019;46:327-47. [PMID: 31010563 DOI: 10.1016/j.clp.2019.02.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
11 Lee SM, Yang S, Kang S, Chang MJ. Population pharmacokinetics and dose optimization of vancomycin in neonates. Sci Rep 2021;11:6168. [PMID: 33731764 DOI: 10.1038/s41598-021-85529-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Stockmann C, Barrett JS, Roberts JK, Sherwin C. Use of Modeling and Simulation in the Design and Conduct of Pediatric Clinical Trials and the Optimization of Individualized Dosing Regimens. CPT Pharmacometrics Syst Pharmacol 2015;4:630-40. [PMID: 26783499 DOI: 10.1002/psp4.12038] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
13 Pham JT. Challenges of Vancomycin Dosing and Therapeutic Monitoring in Neonates. J Pediatr Pharmacol Ther 2020;25:476-84. [PMID: 32839651 DOI: 10.5863/1551-6776-25.6.476] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Van Der Heggen T, Buyle FM, Claus B, Somers A, Schelstraete P, De Paepe P, Vanhaesebrouck S, De Cock PAJG. Vancomycin dosing and therapeutic drug monitoring practices: guidelines versus real-life. Int J Clin Pharm 2021. [PMID: 33913087 DOI: 10.1007/s11096-021-01266-7] [Reference Citation Analysis]
15 Wright WF, Jorgensen SCJ, Spellberg B. Heaping the Pelion of Vancomycin on the Ossa of Methicillin-resistant Staphylococcus aureus: Back to Basics in Clinical Care and Guidelines. Clin Infect Dis 2021;72:e682-4. [PMID: 32901250 DOI: 10.1093/cid/ciaa1360] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Frymoyer A, Schwenk HT, Zorn Y, Bio L, Moss JD, Chasmawala B, Faulkenberry J, Goswami S, Keizer RJ, Ghaskari S. Model-Informed Precision Dosing of Vancomycin in Hospitalized Children: Implementation and Adoption at an Academic Children's Hospital. Front Pharmacol 2020;11:551. [PMID: 32411000 DOI: 10.3389/fphar.2020.00551] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
17 Li ZL, Liu YX, Jiao Z, Qiu G, Huang JQ, Xiao YB, Wu SJ, Wang CY, Hu WJ, Sun HJ. Population Pharmacokinetics of Vancomycin in Chinese ICU Neonates: Initial Dosage Recommendations. Front Pharmacol 2018;9:603. [PMID: 29997498 DOI: 10.3389/fphar.2018.00603] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
18 Liu YX, Wen H, Niu WJ, Li JJ, Li ZL, Jiao Z. External Evaluation of Vancomycin Population Pharmacokinetic Models at Two Clinical Centers. Front Pharmacol 2021;12:623907. [PMID: 33897418 DOI: 10.3389/fphar.2021.623907] [Reference Citation Analysis]
19 Veluzat S, Pauquet E, Sarlangue J. Practice survey on the use of vancomycin in pediatrics in the New Aquitaine region and guidelines of learned societies. Arch Pediatr 2020;27:176-82. [PMID: 32331912 DOI: 10.1016/j.arcped.2020.03.013] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Mcleay RC. Critique of Vancomycin Dose‐Optimizing Software Review. Pharmacotherapy 2019;39:619-619. [DOI: 10.1002/phar.2264] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Stockmann C, Hersh AL, Roberts JK, Bhongsatiern J, Korgenski EK, Spigarelli MG, Sherwin CM, Frymoyer A. Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates. Infect Dis Ther 2015;4:187-98. [PMID: 25998107 DOI: 10.1007/s40121-015-0067-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 5.1] [Reference Citation Analysis]
22 Smit C, Goulooze SC, Brüggemann RJM, Sherwin CM, Knibbe CAJ. Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1-18 Years. AAPS J 2021;23:53. [PMID: 33839974 DOI: 10.1208/s12248-021-00577-x] [Reference Citation Analysis]
23 Chung E, Sen J, Patel P, Seto W. Population Pharmacokinetic Models of Vancomycin in Paediatric Patients: A Systematic Review. Clin Pharmacokinet 2021;60:985-1001. [PMID: 34002357 DOI: 10.1007/s40262-021-01027-9] [Reference Citation Analysis]
24 Padari H, Oselin K, Tasa T, Metsvaht T, Lõivukene K, Lutsar I. Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target? BMC Pediatr 2016;16:206. [PMID: 27931193 DOI: 10.1186/s12887-016-0753-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
25 Tauzin M, Cohen R, Durrmeyer X, Dassieu G, Barre J, Caeymaex L. Continuous-Infusion Vancomycin in Neonates: Assessment of a Dosing Regimen and Therapeutic Proposal. Front Pediatr 2019;7:188. [PMID: 31139607 DOI: 10.3389/fped.2019.00188] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
26 Bhongsatiern J, Stockmann C, Roberts JK, Yu T, Korgenski KE, Spigarelli MG, Desai PB, Sherwin CM. Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration-Time Curve to the Minimum Inhibitory Concentration ≥400 Target. Ther Drug Monit 2015;37:756-65. [PMID: 26562817 DOI: 10.1097/FTD.0000000000000216] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
27 Cotten CM. Adverse consequences of neonatal antibiotic exposure. Curr Opin Pediatr 2016;28:141-9. [PMID: 26886785 DOI: 10.1097/MOP.0000000000000338] [Cited by in Crossref: 61] [Cited by in F6Publishing: 21] [Article Influence: 10.2] [Reference Citation Analysis]
28 Moffett BS, Resendiz K, Morris J, Akcan-Arikan A, Checchia PA. Population Pharmacokinetics of Vancomycin in the Pediatric Cardiac Surgical Population. J Pediatr Pharmacol Ther 2019;24:107-16. [PMID: 31019403 DOI: 10.5863/1551-6776-24.2.107] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
29 Ali AM, Penny MA, Smith TA, Workman L, Sasi P, Adjei GO, Aweeka F, Kiechel JR, Jullien V, Rijken MJ, McGready R, Mwesigwa J, Kristensen K, Stepniewska K, Tarning J, Barnes KI, Denti P; WWARN Amodiaquine PK Study Group. Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing. Antimicrob Agents Chemother 2018;62:e02193-17. [PMID: 30038039 DOI: 10.1128/AAC.02193-17] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
30 Song L, He CY, Yin NG, Liu F, Jia YT, Liu Y. A population pharmacokinetic model for individualised dosage regimens of vancomycin in Chinese neonates and young infants. Oncotarget 2017;8:105211-21. [PMID: 29285245 DOI: 10.18632/oncotarget.22114] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
31 Yoo RN, Kim SH, Lee J. Impact of Initial Vancomycin Trough Concentration on Clinical and Microbiological Outcomes of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children. J Korean Med Sci 2017;32:22-8. [PMID: 27914127 DOI: 10.3346/jkms.2017.32.1.22] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]